OSLO/LONDON SEPTEMBER 03 2020: EXACT THERAPEUTICS AS (“EXACT-Tx”, ticker
EXTX-ME)successfully enrols first patient at the Royal Marsden Hospital in
London, UK, following temporary suspension due to Covid-19.
EXACT-Tx, a clinical stage precision medicine company utilizing Acoustic Cluster
Therapy (ACT®) across multiple therapeutic areas, today announced that the phase
I ACTIVATE study evaluating ACT® in patients with metastatic colorectal cancer
has successfully enrolled the first patient following temporary suspension due
to the Covid-19 pandemic. To date 6 patients have now been enrolled in the study
being led by Professor Udai Banerji at the Royal Marsden Hospital (RMH) in
ACTIVATE study details:
● The first in man ACTIVATE study is a phase I evaluation of the innovative
platform technology, Acoustic Cluster Therapy (ACT®) in the treatment of
patients with metastatic colorectal and pancreatic cancer.
● This study is assessing the safety, tolerability and preliminary efficacy of
ACT® co-administered with standard of care chemotherapy in these patients.
● To date the study has enrolled 6 patients at RMH with Professor Udai Banerji
as principal investigator.
● Additional centres in the UK and Norway are planned as the study progresses.
“We are delighted to restart enrolment in the ACTIVATE study and look forward to
continuing the clinical evaluation of the ACT® platform in patients with
metastatic colorectal cancer" said Udai Banerji, NIHR Professor of Molecular
Cancer Pharmacology and Honorary Consultant in Medical Oncology, Royal Marsden
EXACT Therapeutics CEO, Dr Rafiq Hasan further commented "We are very grateful
to Professor Banerji and the entire team at the Royal Marsden Hospital for their
commitment and dedication to the ACTIVATE study with the enrolment of the first
patient following the suspension due to Covid-19. This important study will
provide important insights regarding the safety, tolerability, pharmacokinetics
and preliminary efficacy of ACT® in the cancer setting.".
● ACT® is a proprietary formulation consisting of microbubbles and microdroplets
that are activated through the application of ultrasound with the consequent
increase in targeted delivery of a co-administered therapeutic agent.
● ACT® is supported by a strong and broad preclinical package demonstrating
therapeutic enhancement in multiple oncology models (pancreatic, breast, colon,
prostate) as well as blood-brain barrier penetration.
● Initial focus of the company is oncology, however the ACT® platform has
potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and
EXACT-Tx is a clinical stage Anglo-Norwegian biotech company developing a
technology platform for targeted therapeutic enhancement – Acoustic Cluster
Therapy (ACT®). ACT® sonoporation is a unique approach to ultrasound-mediated,
targeted drug enhancement – with the potential to significantly amplify the
clinical utility of a wide range of therapeutic agents across a multitude of
indications including within oncology (chemotherapy, immunotherapy), infectious
diseases, and neurological conditions.
For more information contact:
Dr Rafiq Hasan, CEO of EXACT-Therapeutics
Richard Hayhurst/Janet Joy
Tel +44 7711 821527